Some systematic reviews (SRs) have individually evaluated new serum and urinary biomarkers tested in patients with LN, for example, neutrophil gelatinase-associated lipocalin (NGAL) [37], monocyte chemoattractant protein 1 (MCP-1) [38], and interferon-inducible protein 10 (IP-10) [39]. This evidence concerns the gene CCL2 and lobular neoplasia.